Moderna, Inc. (MRNA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Core Insights - Moderna characterized 2025 as a year of execution, achieving a revenue of $1.9 billion, which was at the high end of their projected range [2] - The approval of mNEXSPIKE, their second COVID vaccine, in June contributed significantly to their market presence for the fall season [2] - The company successfully reduced costs by over $2 billion in 2025, exceeding their initial target of $1 billion [3] - As a result of these efforts, Moderna ended the year with a cash balance of $8.1 billion, which includes $600 million from other sources [3]